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Congenital erythropoietic porphyria (CEP), or “Günther disease”, is a rare variant of porphyria. It is an
autosomal recessive disease caused by deﬁcient uroporphyrinogen III synthase (URO-III-synthase), the
fourth enzyme in the heme biosynthetic pathway. We herein report a case of a man with the typical
clinical presentations of hyper- and hypo-pigmentation and blister formation over sun-exposed areas,
mutilation of the ﬁngers, dark-purple urine, and erythrodontia with pinkish ﬂuorescence under a Wood’s
lamp. The diagnosis was conﬁrmed by decreased activity of URO-III-synthase in red blood cells (RBC) and
a porphyrin proﬁle compatible with CEP.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Porphyrias are a diverse group of inherited or acquired heme
biosynthesis disorders. Each sub-type results from deﬁcient activity
of a speciﬁc enzyme in the heme biosynthetic pathway. Congenital
erythropoietic porphyria (CEP) is a rare sub-group with the most
severe photosensitivity andmutilation.1 Typical features of CEP also
include erythrodontia and dark-purple urine. The diagnosis is made
by porphyria proﬁle study and decreased relative enzyme activity.
Here we present a male CEP patient with typical clinical
presentations.Case report
A 28-year-old male visited our dermatology department 3 years
previously due to severe sun-burn after biking. A physical exami-
nation showed extreme scarring with multiple milia formation,
dyspigmentation (Figures 1A and 1B), and loss of acral tissues
(mutilation of the ﬁngers) (Figures 1C and 1D) over frequently
exposed skin areas (i.e., the face, forearms, hands and shins). He
also had brownish teeth (Figures 2A and 2B), dark-purple urine
(Figures 2C and 2D), and icteric sclera emitting pinkish ﬂuorescence
under Wood’s light detection. Porphyria was diagnosed, with
consideration of CEP as the possible sub-type.
The patient had a healthy younger brother, no family history of
porphyria and no consanguinity. After birth, he began to get
sunburned easily, with noticeable blister formation on exposedRoad, Taichung City 40447,
076506.
.
iwanese Dermatological Associatioareas which required sun-protection. When he was 1 year old, his
urine color changed gradually from red-purple to dark-purple. At
that time, porphyria was already the impression, but no further
studies were performed. His teeth became brownish (eryth-
rodontia) while he was in elementary school, and hypertrichosis
developed with irregular hypo- and hyper-pigmentation over
unprotected skin areas upon reaching puberty.
Since his high school years, the patient suffered from frequent
malaise and anemia with hemoglobin ﬂuctuating between 8 and
11 g/dL. Eight years before visiting our department, virus-associated
hemophagocytic syndrome with pancytopenia caused his hemo-
globin to drop from 10 to 3.5 g/dL and he presented with severe
weakness and headache, with splenomegaly proven by sonography.
Furthermore, he suffered transfusion-dependent hemolytic anemia
requiring monthly transfusions of 1000 mL of whole blood to
maintain Hb> 8 g/dL 3 years before our ﬁrst inspection. At this time
his serum ferritin level was up to 6721 ng/mL.
On consultation, his porphyrin proﬁle was analyzed through
his stool and urine using high performance liquid chromatography
and spectroﬂuorometry (Table 1). The urine study showed
extremely increased levels of uroporphyrin isomer I and cop-
roporphyrin isomer I, with a lesser degree of elevation in hepta-,
hexa- and pentacarboxylporphyrin (7-, 6- and 5-COOH-
porphyrin). The stool proﬁle also showed extremely high levels of
coproporphyrin I with an isomer III/I ratio of 0.1 and increased
uroporphyrin I, although isomer III was almost undetectable.
Moreover, the level of 5-COOH-porphyrin isomer III was much
higher than isomer I, and despite no elevation in protoporphyrins,
isocoproporphyrin was mildly elevated in the stool specimen. All
of these ﬁndings were compatible with the clinical impression
of CEP.n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A) Multiple milia around the nose with icteric sclera and hyperpigmented face; (B) obvious dyspigmentation over the shin; (C) severe mutilation of the ﬁngers with
scarring and hypertrichosis over sun-exposed areas; (D) close-up view of the mutilation of the ﬁngers.
W.-H. Lee et al. / Dermatologica Sinica 30 (2012) 62e65 63The activity of URO-III-synthase in red blood cells (RBC) was also
evaluated by URO-III-synthase quasi coupled enzyme assay, and
showed 15 relative units, much lower than the lower limit of 75
units of the reference range (Table 1). Given the clinical presenta-
tion, porphyrin proﬁle, and documented decrease in speciﬁc
enzyme activity, CEP was the ﬁnal diagnosis.
The patient did not accept transplantation due to fears of
possible complications, and avoided sunlight as the only treatment.
Discussion
Porphyrias are a group of disorders related to defects of enzymes
processing the production of heme. Although traditionally catego-
rized as hepatic or erythropoietic forms, they are also classiﬁed into
dermatologic-dominant “non-acute” forms, in contrast to life-
threatening “acute” forms that feature neurologic symptoms
(Figure 3).2
CEP is a very rare disease with only approximately 200 patients
reported worldwide.1,2 The ﬁrst sign of CEP is often during a child’s
1st month, with pinkish or brown porphyrin staining of diapers.
Severe photo-sensitivity and easy-blister formation after exposure
to sunlight then develop in patients with severe forms. Recurrent
wound formation, with secondary bacterial infection, may induce
milia formation, disﬁgurement, and even auto-amputation (muti-
lation) over the digital tips, nose, or ears, while corneal scarring can
lead to blindness.3,4 CEP is the most mutilating type of theporphyrias, and squamous cell carcinomas over the distal ends have
been reported with resorption.5
Large amounts of pathogenic porphyrins are excreted in stools
and urine, which make the urine dark-purple with pinkish ﬂuo-
rescence. Similarly, red-brownish teeth with porphyrins also emit
pinkish ﬂuorescence under aWood’s lamp (erythrodontia), which is
a very special feature or even pathognomonic2 of CEP. In the bones,
fragility and resorption of terminal phalanges may develop.1,3,4,6
Patients with the severe form will have marked hemolytic
anemia and may be transfusion-dependent for life.4 Secondary
splenomegaly may also develop due to the increased uptake of
abnormal erythrocytes and this, in turn, may exacerbate the
anemia, leukopenia, and thrombocytopenia.6,7
In non-acute porphyria, both early onset CEP and erythropoietic
protoporphyria are found, although CEP is found earlier than
erythropoietic protoporphyria. Clinically, swelling erythema with
minor blister formation is seen in erythropoietic protoporphyria,
without pink-ﬂorescent urine. CEP may be similar with hepato-
erythropoietic porphyria in mutilations, but without splenomegaly
or elevated ferritin.1,2,4,8 Porphyria cutaneous tarda is adult onset,
occurs without erythrodontia, and has a better prognosis than CEP.
URO-III-synthase normally catalyzes hydroxymethylbilane to
uroporphyrinogen III, which is the real physiologic intermediate.2,7
The deﬁcient activity of URO-III-synthase directly leads to accu-
mulated hydroxymethylbilane that is mostly non-enzymatically
converted to uroporphyrinogen I. This is then catalyzed by
Figure 2 (A) Brownish teeth with; (B) pinkish ﬂuorescence under Wood’s light detection; (C) the dark-purple urine of our patient (left) compared with a normal person’s light-
yellow urine (right); (D) pinkish ﬂuorescence under Wood’s light detection (left) compared with the normal sample (right).
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tacarboxylporphyrinogen I, and ultimately, coproporphyrinogen I.
This accumulates in the bone marrow (normoblasts and reticulo-
cytes), erythrocytes, plasma, bones, and teeth and undergoes auto-
oxidation to the corresponding porphyrins excreted in urine andTable 1 Porphyrin proﬁles reports in urine and stool specimens and uroporphyri-
nogen III synthase activity in RBC.
Porphyrins RR Elevated
Urine
Uroporphyrin (nmol/24 h) 245345 <30 Yes
Heptacarboxylporphyrin (nmol/24 h) 13284 <9 Yes
Hexacarboxylporphyrin (nmol/24 h) 4482 <8 Yes
Pentacarboxylporphyrin (nmol/24 h) 11538 <10 Yes
Coproporphyrin (nmol/24 h) 50907 <230 Yes
Porphobilinogen (mmol/24 h) 1.5 <2.2
Stool
Uroporphyrin I (mg/24 h) 942 <120 Yes
Uroporphyrin III (mg/24 h) <1 <50 d
Heptacarboxylporphyrin I (mg/24 h) <1 <40 d
Heptacarboxylporphyrin III (mg/24 h) <1 <40 d
Isoheptacarboxylporphyrin (mg/24 h) <1 <30 d
Hexacarboxylporphyrin I (mg/24 h) <1 <10 d
Hexacarboxylporphyrin III (mg/24 h) <1 <10 d
Isohexacarboxylporphyrin (mg/24 h) 523 <10 Yes
Pentacarboxylporphyrin I 3726 <20 Yes
Pentacarboxylporphyrin III (mg/24 h) 204 <20 Yes
Isopentacarboxylporphyrin (mg/24 h) 875 <80 Yes
Coproporphyrin I (mg/24 h) 310608 <500 Yes
Coproporphyrin III (mg/24 h) 32294 <400 Yes
Isocoproporphyrin (mg/24 h) 1640 <200 Yes
Protoporphyrin (mg/24 h) 329 <1500
Coproporphyrin I/III ratio 0.1
Uroporphyrinogen III synthase relative activity, RBC
Relative unit: 15a Reference range: >75
RR: Reference range.
a The proportion of series III isomers formed in relation to total porphyrins (I þ III
isomers) represents the relative activity of uroporphyrinogen III synthase.stools. Since the next enzyme, coproporphyrinogen oxidase, is only
speciﬁc to isomer III, coproporphyrinogen I is not catalyzed
further.7,9
The urine and stool studies of our patient showed extremely
increased levels of uroporphyrin and coproporphyrin, with lesser
elevated hepta-, hexa- and pentacarboxyl porphyrins, as in other
case presentations. In addition, they were all isomer I dominant,
although levels of isomer IIIwere also increased. Extremely elevated
levels of uroporphyrin isomer I and coproporphyrin isomer Iwith an
obviously low ratio of isomer III/I in urine and stools are highly
indicative of CEP.2,7 In addition, the patient had very low URO-III-
synthase activity (only 20% of the lower end of normal), which is
different fromuroporphyrinogen decarboxylase. This, togetherwith
the metabolite elevations and typical clinical presentations, made
for a convincing argument for the diagnosis of CEP.2,7e9
Several papers have reported that cases with highly increased
urinary porphyrin excretion usually have corresponding high
concentrations in stools or plasma.6,8 Themost important ﬁnding in
these reports was the high correlation between the severity of
disease expression and the degree of porphyrin urinary excretion
and porphyrin concentrations in stool and plasma, compatible with
our patient.10,11
However, there was a very special ﬁnding in the porphyrin
proﬁle of our patient e the moderately elevated level of iso-
coproporphyrin in his stool e that may also indicate hepatoery-
thropoietic porphyria (HEP).1,2 This is not typically seen in classic
cases of CEP, and there were several ﬁndings that did not support
the diagnosis of HEP. Clinically, this patient had a virtual patho-
gnomonic picture of CEP, including erythrodontia and obvious
serum iron concentration (ferritin 6721 ng/mL), which are not
features of HEP.2 Secondly, the extremely high coproporphyrin
levels with a smaller increase of pentacarboxylporphyrin and
undetectable hepta- and hexacarboxylporphyrin in his stool (and
urine), all indicated normal function of uroporphyrinogen decar-
boxylase, the speciﬁcally defective enzyme in HEP.2,7,12,13
Figure 3 The pathway of haem biosynthesis. The red boxes represent enzymes, and the blue boxes indicate the relative porphyria subtypes, 7-, 6- and 5-COOH-porphyrinogen
(hepta-, hexa- and pentacarboxylporphyrin), respectively. The acute form includes: AADDP, AIP, VP and HCP, while the non-acute form includes: PCT, EEP, CEP and HEP, where
AADDP¼d-aminolevulinic acid dehydratase deﬁciency porphyria; AIP¼acute intermittent porphyria; CEP¼congenital erythropoietic porphyria; PCT¼porphyria cutanea tarda;
HEP¼hepatoerythropoietic porphyria; HCP¼hereditary coproporphyria; VP¼variegate porphyria; EPP¼erythropoietic protoporphyria.
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suppressing erythropoiesis and then decreasing porphyrin forma-
tion, however, iron overload is the really big problem, which was
found in our patient.14 Several other treatment modalities have
been suggested in previous reports, such as, beta-carotene,15 oral
charcoal,16,17 and splenectomy, however, these were not performed
on our patient. Stem cell transplantation, which was refused by our
patient, is currently the only curative treatment, and several
successful cases have been reported.6,18e20
In summary, we described the typical clinical and biochemical
ﬁndings of CEP in a young Taiwanese male. In the past, most
patients have died by the age of 40 years, however, improvements
in supportive care (particularly the use of antibiotics) have
improved the prognosis, although the hematological complications
may be fatal.21 Gene therapy by virus-mediated transfer of func-
tional UROS cDNA into pathogenic hematopoietic stem cells has
been reported in a mouse model, with complete and long-term
enzymatic, metabolic, and phenotypic correction. This may be an
important curative methodology in the future.22
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